1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsEDS Accelerator Award is sponsored by American Cancer Society. Accelerates the development of promising cancer research projects.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
RFA: Extramural Discovery Science Accelerator Award | Research Funding RFA: Extramural Discovery Science Accelerator Award The intent of the Extramural Discovery Science (EDS) Accelerator Award is to support the commercialization of an ongoing cancer research project and to validate and de-risk technologies.
Proposals should address key experiment(s) required to move findings toward commercialization that do not easily fit into traditional grant funding mechanisms. This mechanism is not designed to initiate new projects or develop new directions for an ongoing project.
The proposal should be commercially driven with the PI having a plan to license the technology, either to an established company or a start-up if the experiment(s) are successful.
Examples of research that align with the focus of this funding initiative include but are not limited to: Dosing, toxicity and/or efficacy testing Testing of biopsies or other patient samples to correlate clinical outcome Technologies for healthcare delivery Accelerator awardees will become part of an entrepreneurial collaborative learning community focused on technology commercialization.
Grantees will have access to both educational programming developed by the ACS BrightEdge team and the team itself. Applications submitted through June 1, will be reviewed in July. Applications submitted after June 1, will be reviewed in December.
Be a current or former ACS grantee (includes IRG pilot grant awardees) or a former ACS postdoctoral fellow. Have a full-time faculty appointment, at an eligible US institution. Applicants may be at any career stage.
Be motivated to commercialize their technology. Budgets can be up to $75,000 total costs for a one-year term. Indirect costs are not allowed.
Engineering and Physical Sciences Medical - Clinical Science
According to the current listing, eligibility includes: Varies; refer to specific program guidelines. Confirm the full requirements in the official notice before applying.
Applications for EDS Accelerator Award are due December 1, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
EDS Accelerator Award is funded by American Cancer Society. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read articleCDC-RFA-DP-27-0023 puts the National Breast and Cervical Cancer Early Detection Program, the National Comprehensive Cancer Control Program, and the National Program of Cancer Registries into a single competition closing February 5, 2027. Three statutorily separate eligibility pools, one application deadline, and an award count that maps onto the incumbent footprint. Here is how to read that.
Read articleCDMRP reissued the FY26 BCRP Breakthrough Award Levels 1 and 2 and the Clinical Research Extension Award on September 3, 2026, with a November 4 pre-application deadline and a November 18 full application deadline. Round one closed July 8. The arithmetic across both windows accounts for nearly the entire FY26 appropriation — which tells you what kind of second chance this is.
Read article